Entrada Therapeutics
About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).
Stock Symbol: TRDA
Stock Exchange: NASDAQ
CONNECT
“Most targets for drug development are actually intracellular,” says Dipal Doshi, President and CEO of Entrada Therapeutics. “Think about how many drugs can be made that can help patients if we can figure out a way to effectively get inside the cell…that’s why Entrada’s important.”
28 articles with Entrada Therapeutics
-
Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
11/22/2022
Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 5th Annual HealthCONx Virtual Conference on Tuesday, November 29, 2022 at 3:55 p.m. Eastern Time.
-
Entrada Therapeutics Reports Third Quarter 2022 Financial Results
11/7/2022
Entrada Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and highlighted recent business updates.
-
Entrada Therapeutics Reports Second Quarter 2022 Financial Results
8/11/2022
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the second quarter ended June 30, 2022 and highlighted recent business updates.
-
Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week's Movers & Shakers.
-
Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer
7/19/2022
Entrada Therapeutics, Inc. today announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately.
-
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
6/1/2022
Entrada Therapeutics, Inc. announced that the Company will participate in-person at the Goldman Sachs Global Healthcare Conference.
-
Entrada Therapeutics Reports First Quarter 2022 Financial Results
5/12/2022
Entrada Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and highlighted recent business updates.
-
Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022
5/11/2022
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today presented updates to its two lead programs at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics Conference.
-
Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference - May 10, 2022
5/10/2022
Entrada Therapeutics, Inc. announced that Dipal Doshi, President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference.
-
Dozens of life sciences companies are relocating to accommodate more employees and production capacities.
-
Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
3/15/2022
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the fourth quarter and full year ending December 31, 2021 and highlighted recent business updates.
-
Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
2/23/2022
Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle therapeutics as a new class of medicines, announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference.
-
Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel
1/5/2022
Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle therapeutics as a new class of medicines, announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately.
-
Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes
12/17/2021
Entrada Therapeutics, Inc. today announced that the Company will be added to the Russell 2000 ® and Russell 3000 ® Indexes as part of the planned fourth quarter IPO additions, effective after the U.S. market opens on December 20, 2021.
-
Entrada Therapeutics Reports Third Quarter 2021 Financial Results
12/9/2021
Entrada Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021 and highlighted recent business updates.
-
Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
11/18/2021
Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 12:10 p.m. Eastern Time.
-
Vaxxinity set its initial public offering price at $13 per share, raising $76 million. The company was launched in April via consolidation of the vaccine development efforts of COVAXX and United Neuroscience.
-
Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering
10/29/2021
Entrada Therapeutics, Inc., a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle therapeutics as a new class of medicines and aiming to become the world’s foremost intracellular therapeutics company, announced the pricing of its upsized initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share.
-
It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.